Core Viewpoint - Aikoma Medical has achieved significant revenue in its first year of commercialization, with several million yuan in earnings, following a successful over 100 million yuan Pre-B round financing aimed at accelerating the development and commercialization of its innovative cardiac electrophysiology technologies [4][7]. Group 1: Company Overview - Aikoma Medical focuses on the cardiac electrophysiology sector, particularly in developing pulse field ablation (PFA) technology, which selectively targets myocardial cells without damaging surrounding tissues [4][5]. - The company has established a comprehensive product matrix that includes a three-dimensional mapping system and a range of electrophysiological consumables [4][6]. - Aikoma Medical's PFA system has achieved a 100% immediate pulmonary vein isolation rate during procedures, with a 12-month follow-up success rate of 87.7% [6][7]. Group 2: Technology and Innovation - The PFA system features a unique variable circle diameter design to accommodate various clinical scenarios, enhancing its adaptability [8]. - Aikoma Medical has developed an intelligent algorithm to monitor catheter positioning, improving the effectiveness of the ablation process [6]. - The company is leveraging AI technology to process vast amounts of surgical data, enhancing the precision of three-dimensional cardiac models and simplifying surgical procedures [7][8]. Group 3: Market Potential and Investment - The global cardiovascular market is the second largest medical device market, with cardiac electrophysiology experiencing over 20 years of continuous growth [4]. - Investors recognize the broad market potential for PFA technology, which is becoming a mainstream treatment in the cardiac electrophysiology field [8]. - Aikoma Medical's products have been implemented in nearly 100 hospitals nationwide, with significant market access facilitated by successful procurement processes in regions like Beijing [7].

Investment Rating - The industry investment rating is maintained at "Overweight" [3] Core Insights - The medical consumables sector saw a weekly increase of 1.72%, outperforming the CSI 300 index by 0.23 percentage points [5][10] - The current PE ratio for the medical consumables sector is 37.73X, with a PB ratio of 2.71X, indicating a slight increase in valuation metrics compared to the previous week [6][18][20] Industry Performance - Over the past month, the medical consumables sector has shown a relative return of 9%, while the absolute return over the last 12 months is 22% [4] - The sector's performance is compared to other sub-sectors, with notable fluctuations in the medical and pharmaceutical industries [12] Industry Dynamics and Key Announcements - The 2026 National Health System Grassroots Health and Financial Work Conference emphasized the importance of strengthening basic medical services and expanding rehabilitation and nursing services, which is expected to drive demand for consumables [7][21] - The focus on grassroots healthcare institutions is anticipated to enhance the demand for consumables related to common and chronic diseases, as well as rehabilitation equipment [21] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the context of ongoing procurement normalization [8][23] - Companies with a diverse product line and strong market presence in high-value consumables, such as HuiTai Medical and MaiPu Medical, are highlighted as potential investment opportunities [8][23]